BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24840555)

  • 1. APOBEC3 signature mutations in chronic lymphocytic leukemia.
    Rebhandl S; Huemer M; Gassner FJ; Zaborsky N; Hebenstreit D; Catakovic K; Grössinger EM; Greil R; Geisberger R
    Leukemia; 2014 Sep; 28(9):1929-32. PubMed ID: 24840555
    [No Abstract]   [Full Text] [Related]  

  • 2. APOBEC3-mediated restriction of RNA virus replication.
    Milewska A; Kindler E; Vkovski P; Zeglen S; Ochman M; Thiel V; Rajfur Z; Pyrc K
    Sci Rep; 2018 Apr; 8(1):5960. PubMed ID: 29654310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.
    Roelofs PA; Martens JWM; Harris RS; Span PN
    Clin Cancer Res; 2023 May; 29(9):1658-1669. PubMed ID: 36478188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
    Swanton C; McGranahan N; Starrett GJ; Harris RS
    Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis.
    Maciejowski J; Chatzipli A; Dananberg A; Chu K; Toufektchan E; Klimczak LJ; Gordenin DA; Campbell PJ; de Lange T
    Nat Genet; 2020 Sep; 52(9):884-890. PubMed ID: 32719516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
    Kanu N; Cerone MA; Goh G; Zalmas LP; Bartkova J; Dietzen M; McGranahan N; Rogers R; Law EK; Gromova I; Kschischo M; Walton MI; Rossanese OW; Bartek J; Harris RS; Venkatesan S; Swanton C
    Genome Biol; 2016 Sep; 17(1):185. PubMed ID: 27634334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
    Petljak M; Green AM; Maciejowski J; Weitzman MD
    Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3 enzymes restrict marginal zone B cells.
    Beck-Engeser GB; Winkelmann R; Wheeler ML; Shansab M; Yu P; Wünsche S; Walchhütter A; Metzner M; Vettermann C; Eilat D; DeFranco A; Jäck HM; Wabl M
    Eur J Immunol; 2015 Mar; 45(3):695-704. PubMed ID: 25501566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide mutation avalanches induced in diploid yeast cells by a base analog or an APOBEC deaminase.
    Lada AG; Stepchenkova EI; Waisertreiger IS; Noskov VN; Dhar A; Eudy JD; Boissy RJ; Hirano M; Rogozin IB; Pavlov YI
    PLoS Genet; 2013; 9(9):e1003736. PubMed ID: 24039593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting APOBECs in cancer: It's about timing.
    Hata AN; Larijani M
    Cancer Cell; 2024 Apr; 42(4):497-501. PubMed ID: 38593778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of cytosine deaminases enables base-resolution methylome mapping using a single enzyme.
    Vaisvila R; Johnson SR; Yan B; Dai N; Bourkia BM; Chen M; Corrêa IR; Yigit E; Sun Z
    Mol Cell; 2024 Mar; 84(5):854-866.e7. PubMed ID: 38402612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The underexplored role of APOBEC3 enzymes in autoimmune diseases.
    Liu YT; Meng XY
    Rheumatology (Oxford); 2024 May; 63(6):e166-e167. PubMed ID: 38060252
    [No Abstract]   [Full Text] [Related]  

  • 13. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
    Sutton LA; Rosenquist R
    Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.
    Huemer M; Rebhandl S; Zaborsky N; Gassner FJ; Hainzl S; Weiss L; Hebenstreit D; Greil R; Geisberger R
    Eur J Immunol; 2014 Dec; 44(12):3747-57. PubMed ID: 25179679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AID/APOBEC deaminases and cancer.
    Rebhandl S; Huemer M; Greil R; Geisberger R
    Oncoscience; 2015; 2(4):320-33. PubMed ID: 26097867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10 regulates Aicda expression through miR-155.
    Fairfax KA; Gantier MP; Mackay F; Williams BR; McCoy CE
    J Leukoc Biol; 2015 Jan; 97(1):71-8. PubMed ID: 25381386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active DNA demethylation-The epigenetic gatekeeper of development, immunity, and cancer.
    Prasad R; Yen TJ; Bellacosa A
    Adv Genet (Hoboken); 2021 Mar; 2(1):e10033. PubMed ID: 36618446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.
    Wiecek AJ; Jacobson DH; Lason W; Secrier M
    Front Cell Dev Biol; 2021; 9():698659. PubMed ID: 34307377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator.
    Takei H; Fukuda H; Pan G; Yamazaki H; Matsumoto T; Kazuma Y; Fujii M; Nakayama S; Kobayashi IS; Shindo K; Yamashita R; Shirakawa K; Takaori-Kondo A; Kobayashi SS
    Int J Hematol; 2020 Sep; 112(3):395-408. PubMed ID: 32533515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia.
    Gassner FJ; Zaborsky N; Feldbacher D; Greil R; Geisberger R
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.